Icon Plc $ICLR Shares Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC increased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 13.1% in the fourth quarter, Holdings Channel reports. The firm owned 542,996 shares of the medical research company’s stock after buying an additional 62,892 shares during the period. Icon comprises 1.3% of Stephens Investment Management Group LLC’s investment portfolio, making the stock its 11th largest holding. Stephens Investment Management Group LLC’s holdings in Icon were worth $98,945,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Geneos Wealth Management Inc. increased its position in shares of Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the last quarter. Sanctuary Advisors LLC increased its position in shares of Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after purchasing an additional 56 shares during the last quarter. Signaturefd LLC increased its position in shares of Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock worth $117,000 after purchasing an additional 72 shares during the last quarter. New Wave Wealth Advisors LLC increased its position in shares of Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock worth $270,000 after purchasing an additional 72 shares during the last quarter. Finally, 1900 Wealth Management LLC increased its position in shares of Icon by 4.4% during the 4th quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock worth $443,000 after purchasing an additional 103 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Stock Performance

Shares of ICLR opened at $116.38 on Friday. The stock has a 50-day simple moving average of $109.72 and a 200-day simple moving average of $144.82. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market capitalization of $9.40 billion, a PE ratio of 15.75, a PEG ratio of 3.04 and a beta of 1.23. Icon Plc has a 1 year low of $66.57 and a 1 year high of $211.00.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Weiss Ratings downgraded Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Leerink Partners set a $125.00 target price on Icon in a report on Monday, May 4th. Zacks Research cut Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Finally, Citigroup lowered their target price on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $149.38.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.